From the PHOSITA to the MOSITA: Will “Secondary Considerations” Save Pharmaceutical Patents from Artificial Intelligence?
Crossref DOI link: https://doi.org/10.1007/s40319-020-00953-8
Published Online: 2020-06-24
Published Print: 2020-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Fabris, Daniele
Text and Data Mining valid from 2020-06-24
Version of Record valid from 2020-06-24
Article History
First Online: 24 June 2020